RT @KevinH_PhD: Insightful commentary by @KCKlatt: “it’s time for food and nutrition advocates, scientists and professionals to call out th….

Yet another GLP-1 agonist completes a phase 3 trial in adults with overweight or obesity. 🧪⚖️. Ecnoglutide, a subcutaneous once weekly injection, generated 13.2% weight loss in the highest dose vs 0.1% in placebo. 💉📉. Adverse events were comparable to the rest of the class of

The long awaited triple agonist retatrutide phase 3 data is still pending ⏳🧪. However, a body composition subanalysis of the phase 2 data is newly published 📄 showing lean mass loss of 38% of total weight loss 💪📉. This ratio of lean mass to fat mass loss is comparable to

RT @Mrwailee: She did it! Our dear #urps fellow @allie_tabakin is leaving us after 3 years 🙀. 👩🏻‍🎓tireless mentor to @ZuckerSoM students @S….

China approves the first dual glucagon/GLP1 agonist, mazdutide, for chronic weight management. This quickly follows its NEJM phase 3 study demonstrating 14.8% weight loss in 48 weeks. NEJM: Press release:

The etiology of obesity is most often multifactorial- a combination of environmental factors and genetic predisposition among thousands of genes. However, a portion of cases are due to a single genetic cause, such as in the leptin-melanocortin pathway. Recognizing monogenic

Real-world comparison of semaglutide/tirzepatide (GLP‑1/GLP‑1+GIP) vs bariatric surgery. 📉 In a real-world matched study of 14,152 pts:.At 2 years:.• Surgery: −25.7% total weight loss (TWL).• GLP-1s (semaglutide/tirzepatide): −5.3% TWL (ITT); −7.6% (per-protocol).• HbA1c.

An osteoporosis treatment algorithm.

In the CagriSema trial, patients on sub-maximal doses lost MORE weight than those on the maximum (2.4mg) dose! . This demonstrates the need for flexible dosing in the clinic- not all patients need or can tolerate the maximum dose. Insurance companies don't seem to get that.

Summary of REDEFINE 1 and REDEFINE 2 trials with CagriSema, presented this week at #ADA2025 and published in NEJM:. REDEFINE 1:.• 👥 3,417 participants with obesity or overweight (without diabetes) treated with CagriSema achieved a 22.7% weight loss after 68 weeks, compared to

RT @IrinaBancos: Ep 58: Hydrocortisone vs Prednisone for Post-Surgical Recovery in Endoge. via @YouTube. @RSandoo….

GLP-1RAs were associated with an increased risk of GERD and cholelithiasis but did not significantly increase the risk of pancreatitis, cholecystitis, intestinal obstruction, or other serious gastrointestinal or biliary events. GLP-1 RAs were associated with increased the risk.

RT @AliceYYCheng: 🤯 22% body weight reduction on treatment with 93% of that being fat mass. Main side effects muscle spasm, diarrhea, acne.….

What is the impact of tirzepatide on body composition? 🤔. There was an absolute loss in lean mass 💪⬇️, however there was a GREATER loss in fat mass 🧈🔥. Thus, there was an increase in lean mass as percent body composition 📊💪. This correlates with what we see clinically —

The story of the metformin the wonder drug continues!.

We’ve gone from 2 to over a dozen trials of GLP1s in alcohol use disorders in only a few years. This comes on the heels of numerous observational and pharmacoepidiologic data supporting a reduction in alcohol use in GLP1 users. #ADA2025 #ADASciSessions

CGMs can cause significant mental and emotional distress, AND we don’t ask about it. Physicians need to inquire of the level of distress it may cause so we can maximize the benefit and limit the risk. Excellent talk Dr. Estelle M Everett. #ADA2025

A continuous glucose monitor is not for everyone! . #ADA2025

Continuous glucose monitors are helpful tools, but alarm distress is real ⏰. Data overload, desensitization and distrust in the device are all drivers of alarm distress and ultimately poorer glucose control. Excellent talk by Dr. Gwendolyne Jack. #ADASciSessions #ADA2025

Continuous glucose monitors are an excellent tool… when they work!. Studies report up to 26% early failure rate of these devices. #ADA2025 #ADASciSessions